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Abstract

The use of continuous positive airway pressure (CPAP) in asthma has been a point of debate over the past several years. Various studies,
including those on animals and humans have attempted to understand the role and pathophysiology of CPAP in patients with either well
controlled or poorly controlled asthma. The aim of this manuscript is to review the currently available literature on the physiologic and
clinical effects of CPAP in animal models of asthma and on humans with stable asthma.
KEYWORDS: Asthma, bronchoconstriction, continuous positive airway pressure
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Accepted: 10.06.2019

INTRODUCTION
Bronchial asthma is a common chronic airway disorder with variable and recurring symptoms, including airway obstruction, bronchial hyperresponsiveness, and underlying inflammation. It is characterized by heterogeneity since the numerous phenotypes associated with it have been proposed recently [1].
Despite advances in medical treatment, the prevalence of patients with uncontrolled asthma continues to be relatively
high in everyday clinical practice [1]. Asthma therapies, such as bronchodilator medications (typically in combination
with inhaled corticosteroids) and a more recent technique called bronchial thermoplasty are focusing on airway smooth
muscle (ASM), taking into consideration its importance in airflow obstruction [2]. Over the past years, the effect of positive
airway pressure as a non-pharmacologic strategy to improve asthma control has become an object of scientific interest
[3]. This review article aimed to summarize the available literature on such effects both in animal models of asthma and
human subjects with stable asthma.
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Asthma Pathophysiology and Effect of Mechanical Ventilation
Our insight with regard to bronchial asthma has changed
considering the advances in molecular phenotyping, which
has revealed heterogeneous phenotypes within the asthmatic
population. Exposure to various environmental factors such
as viruses and inhaled antigens trigger an immune response
directed at the T-helper type-2 (Th2) cells. Initial exposure to
the allergens leads to sensitization; however, repeated exposure triggers a cascade of cellular and immune responses that
culminates in airway hyperactivity and symptoms of asthma.
The interaction between the dendritic cells and the antigen
activate the Th0 and subsequently Th2 cells which release IL4, IL-5, and IL-13. IL-4 and IL-13 stimulate B-cells to synthesize IgE, which causes the mast cells to release LTC4, PGD2,
and histamine that result in goblet cell hyperplasia, edema,
mucus secretions, and bronchial smooth muscle contraction.
IL-5 stimulates eosinophils to release pro-inflammatory mediators causing an inflammatory process and thus bronchoconstriction.
Mechanical ventilation is reportedly associated with ventilation-induced lung injury and an augmented inflammatory
response [4]. Tsangaris et al. [5] studied the inflammatory
response triggered by the use of mechanical ventilation for
extended durations in patients without acute lung injury. The
study outcomes revealed that during mechanical ventilation
the total bronchoalveolar lavage (BAL) protein increased but
the BAL phospholipids decreased. Additionally, there was a
reduction in the aggregation of surfactants. However, there
was an increase in the inflammatory markers, including the
platelet activating factor (PAF), PAF-acetylhydrolase and neutrophils after 1 week, despite being partially remitted after
2 weeks of mechanical ventilation. This study showed that
prolonged mechanical ventilation in patients without acute
lung injury is associated with the presence of inflammatory
markers and alterations in surfactant.
Chiumello et al. [6] examined whether injurious ventilatory
strategies would increase the release of inflammatory mediators including tumor necrosis factor-alpha (TNF-α) and macrophage inflammatory protein-2 (MIP-2) concentrations into
the systemic circulation in a lung injury model. They concluded that the release of cytokines into the systemic circulation was influenced by the ventilatory modality, which may
be eventually be relevant in developing multisystem organ
failure.
Paone et al. [7] observed the effects of long-term noninvasive ventilation (NIV) on systemic inflammatory response in
patients with COPD. Sputum analysis in the NIV versus oxyMAIN POINTS
•

Non-invasive ventilation is essential in the treatment of
bronchial asthma.

•

CPAP may be used to assist in inhaled therapy to ensure
better bronchodilation.

•

Short durations of CPAP may effectively treat chronic
airway hyperresponsiveness which is a more aceptable
modality than prolonged CPAP treatment.

gen therapy group showed similar levels of human neutrophil
peptides (HNP), IL-6, IL-10, and TNF-α (p>0.5). However,
the NIV group had higher HNP and IL-6 systemic levels and
lower IL-10 concentrations (p<0.001). The authors concluded that the beneficial effects of NIV on lung mechanics in
COPD patients may be negated by its potential effects on the
inflammatory system.
Contrarily, Borel et al. [8] examined the effects of NIV on
inflammatory markers in patients with mild obesity hypoventilation syndrome and reported no significant variations between the inflammatory and anti-inflammatory cytokines.
NIV did not affect the inflammatory, metabolic, or cardiovascular markers in patients with mild obesity hypoventilation
syndrome.
Overall, NIV may be essential in treating the acute exacerbations of bronchial asthma by avoiding invasive mechanical
ventilation. This method has reportedly decreased the risk of
triggering an acute inflammatory cascade that will potentiate
lung injury.
Airway Smooth Muscle and Asthma Control
Asthma pathogenesis is influenced by the ASM function
both directly by obstructing the airflow by contracting it and
indirectly by airway remodeling and modulating airway inflammation. These processes interact with each other to ensure that the net contribution of ASM to asthma is manifold
and complex [2]. In asthma, the contributing mechanisms
of airway hyperresponsiveness (AHR) include increased dynamic muscle stiffness, increased vagal tone, and cytokinepotentiated increases in intracellular free calcium. Increased
ASM mass has been identified as a hallmark of asthma and
its abundance is particularly overt in cases of fatal or severe
asthma. Moreover, excessive ASM mass and airway wall
thickening is associated with AHR [2]. Several studies have
reported that the mechanical stretch imposed on an isolated
ASM may activate the signaling cascade of several cytoskeletal proteins that are implicated in actin dynamics, myosin
light chain phosphorylation, and cytoskeletal organization
[2, 3, 9-14].
Deep breathing has been reported to reverse bronchoconstriction in healthy individuals and a small proportion of
asthma patients due to changes in the actin-myosin interaction [15]. However, most asthma patients can no longer take
deep breaths. It is believed that the dynamic stretch of the
ASM during an acute asthma exacerbation at decreased tidal
volumes and high end-expiratory lung volumes prevail over
the beneficial outcome of a mean stretch of ASM attained via
deep inspiration (DI) [16].
Animal Studies
Animal studies have provided valuable information regarding the effects of lung volumes and CPAP on ASM. A study
by McClean et al. [17] examined the in vitro contractility of
ASM after being exposed to carbachol in a group of sheep
whose tidal volume was restricted using a corset for 4 weeks.
The corset was adjusted to reduce their functional residual
capacity (FRC) by nearly 25%. They also measured the number of deep inspirations. ASM excision revealed higher and
shorter contractile responses and discovered that ASM cells
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can alter the organization of their contractile apparatus in
response to changes in volume. The duration of maintaining
this effect was not transient, since the results were obtained
after excising the muscle. This study allowed for a potential
explanation for the changes in airway responsiveness observed in obese subjects.
To understand the effects of CPAP on patients with asthma, it
is imperative to understand the effect of CPAP on normal lung
function. Xue et al. [18-21] designed four studies in rabbits,
ferrets, and mice where CPAP versus sham CPAP was applied
through a tracheostomy. The first study suggested that a 4-day
application of mechanical strain to the lungs resulted in lower respiratory system responsiveness to acetylcholine in vivo
[18]. The airways isolated from the lungs of animals subjected to CPAP were less responsive to acetylcholine in vitro than
those of the control group. In the second study, the authors
found that the ASM of ferrets subjected to CPAP for 14 days
increased the luminal areas of the intrathoracic trachea and
intraparenchymal airways and lower levels of myosin light
chain phosphorylation, which accounted for the decreased
AHR levels observed in vivo [19]. In the third study, the authors hypothesized that intermittently applying CPAP could
reduce airway reactivity and that this effect could last for
minimum 24 hours. They also reported that CPAP suppressed
AHR caused by ovalbumin-induced airway inflammation
[20]. In the last study, the same authors reported that only
2 hours of CPAP decreased airway resistance in vitro for the
following 6 hours and that there were molecular changes including the IL-13-induced downregulation of Akt phosphorylation [21]. Therefore, considerably short durations of CPAP
therapy may effectively treat chronic AHR, which would be
considered as a more acceptable modality to several patients
than prolonged CPAP treatment [22].
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Human Studies
Similar to the study by McClean et al. [17], Ding et al. reported increased airway resistance in normal individuals subjected to the methacholine challenge when asked to breathe
at 0.5 l below their FRC [23]. However, airway resistance
decreased in normal subjects when they were instructed to
breathe 0.5 l above their FRC. The authors concluded that
low lung volumes may uncouple the airway and parenchyma, which was measured as a decreased elastic load leading
to ASM shortening. Skloot et al. [24] compared ten asthmatics with ten healthy controls, and demonstrated that prohibiting deep breaths was associated with hyperresponsiveness to
inhaled methacholine in normal subjects. This AHR persisted
for some time even after permitting deep inspiration. These
findings suggest that AHR is magnified at low lung volumes
in response to inhaled irritants. Martin et al. [25] studied the
effects of CPAP for a one minute when applied to eight asthmatic patients with aerosolized histamine induced bronchospasm. The outcomes indicated that CPAP resulted in a decreased work of breathing, trans-diaphragmatic, and pleural
pressures and/or pressure time product despite an increased
minute ventilation in seven out of eight subjects. Furthermore,
the authors argued that despite increasing the end-expiratory
lung volume, CPAP assists in inflating the chest to reduce the
peak pleural pressure generated by the inspiratory muscles.
Furthermore, they noticed a large decrease in pulmonary re-

sistance during CPAP use, which increased after withdrawal.
Consistent decrease in inspiratory work per liter of ventilation
was caused both by the decrease in pulmonary resistance
and by the assistance given to inspiratory muscles by CPAP.
In a later study, Martin et al. [26] evaluated seven non-apneic,
non-snoring asthmatics to measure improvements in nocturnal asthma with the use of nasal CPAP. Two subjects demonstrated an increase in FEV1 levels after CPAP, contrary to the
other subjects. Lin et al. [27] studied the effects of nasal CPAP
in fifteen patients. Eight subjects received nasal CPAP at 8 cm
H2O for 10 min while the remaining patients received a sham
CPAP. The patients who underwent nasal CPAP demonstrated
a significantly increased provocation dose causing a 20% decline in FEV1 (PD20FEV1) and better bronchodilator response
to inhaled salbutamol.
Briefly using positive airway pressure by a computercontrolled syringe was applied in 24 asthma patients who
were challenged with methacholine [28]. The patients were
grouped according to their FEV1 response to DI. This study
aimed to evaluate respiratory resistance using forced oscillation. The change induced by the positive-pressure inflation
in resistance was significantly greater than that induced by
active DI only in the impaired DI response group. Additionally, those with impaired DI response had lower spontaneous inspiratory volume percentages. The authors concluded
that positive-pressure inflation may open closed airways that
could not be opened by active DI. Improvements associated
with the reduction of airway obstruction by positive-pressure
inflation over active DI was related to an increase in the percent inspired volume. The authors speculated that positivepressure inflation may have increased the stretch of smooth
muscles within the airway wall. They classified the asthmatics according to their response to DI as either responders or
non-responders and measured airway resistance via force
oscillation. The passive DI maneuver was set below 90%
of inspiratory capacity and the reduction in resistance by
positive-pressure inflation was significantly greater than that
by active DI in the impaired DI response group. It has been
stated that asthma leads to periodic airway closure and lung
volume de-recruitment. However, deep breaths may not result in broncho-protection if they are trapped beyond a point
of larger airway closure in such airways. Finally, Lin et al. [29]
reported that patients with obstructive sleep apnea (OSA)
without asthma, but with a positive methacholine challenge
test, showed a decrease in their hyperreactivity to methacholine after two to three months of nasal CPAP therapy.
Busk et al. [30] observed the effects of nocturnal CPAP for 7
days, set at 8-10 cmH2O versus sham CPAP in patients with
clinically controlled mild asthma, to check for the presence
of any decrease in airway reactivity. A methacoline challenge
test was performed at baseline and 1 week after the use of
nocturnal CPAP. The CPAP group (n=16 patients) showed
a significant decrease in airway reactivity, while the sham
group (n=9 patients) did not. Additionally, the CPAP group
demonstrated a 15% increase in FEV1 following an inhaled
bronchodilator. Although this study demonstrated that using
nocturnal CPAP reduced airway reactivity in asthma patients,
it failed to exclude subjects with sleep apnea or provide data
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regarding the their body weight, either of which could potentially influence airway strain [30].
D´Amato et al. [31] studied the efficacy of automatic CPAP as
an adjunct therapy in patients with severe persistent asthma
to ameliorate their symptoms, reduce PEF variability, and
improve the patients’ quality of life. This study included ten
patients with more than a 25-year history of asthma. Subjects
with sleep apnea were excluded after polysomnographic
exam. CPAP, with a mean positive airway pressure of 5.3±1.3
cmH2O, was applied for seven nights through a full-face
mask. Lung function, asthma control, and quality of life were
measured at baseline, during the treatment period, and within 1 month from baseline. The study showed a reduction in
PEF variability during the 2 weeks on CPAP treatment, along
with a significant improvement in the asthma control score.
Given the increasing number of asthmatic patients with OSA,
it is important to understand the role of CPAP in these patients. Wenzel et al. [32] noted that after administering CPAP
for in 41 subjects with OSA, a small number of patients
demonstrated a mild to moderate AHR to histamine induction without any clinical relevance. Devouassoux et al. [33]
studied 57 subjects with no history of smoking with OSA and
without asthma and found that 1 and 4 weeks of CPAP treatment increased AHR in OSA patients despite no changes in
FEV1 or symptoms. AHR was not related to OSA severity and
had no influence on CPAP compliance.
Korczynski et al. [34] randomized 101 non-asthmatics with
OSA, of whom 40% were smokers, into the CPAP group and
the no CPAP group for 3 weeks. The observed that increased
AHR in those treated with CPAP, despite no changes in the
symptoms. AHR was not related to OSA severity and had
no influence on CPAP compliance. Furthermore, they found
no relationship between AHR and smoking status. The authors speculated that positive pressure might have triggered
a naso-bronchial reflex. In OSA, multiple pathways may be
responsible to develop mucosal inflammation, including the
desaturation-re-oxygenation sequence that generates oxidative stress and contributes to bronchial inflammation. Furthermore, IL-8 in induced sputum was significantly correlated
with the severity of sleep apnea and oxygen desaturation. A
major increase in bronchial neutrophils was accompanied by
a high bronchial concentration of IL-8 [35].
In addition to the aforementioned studies, Davies et al. [36]
conducted a systematic review to evaluate if CPAP treatment
in asthmatic patients with co-existing OSA helped improve
their quality of life and asthma-related symptoms. The study
population was treated with CPAP for a mean duration of
19.5 weeks and although it showed that mean quality of life
improved with CPAP, there was no significant improvement
in FEV1 (p=0.84). The authors concluded that the patients’
quality of life can improve via CPAP; however, this effect was
more notable in patients with either severe OSA or poorly
controlled asthma.
Aerosol Deposition with the Use of Positive Airway Pressure
Nebulizer therapy is commonly used in patients with asthma
to help reduce bronchial constriction and support breathing.
In acute cases, nebulizer therapy is administered in conjunc-

tion with positive airway pressure. Furthermore, it is important to understand the effectiveness of these two therapies in
conjunction and whether positive airway pressure has beneficial effects on aerosol deposition within the lungs.
In healthy individuals with no history of asthma, Franca et al.
[37] performed a study in 13 patients and showed no differences in the aerosol deposition when using noninvasive positive airway pressure than when administering nebulization
without pressure support. However, Tsai et al. [38] conducted a study in patients with stable asthma and showed that
the administration of aerosolized beta2-agonists with positive
end pressure appeared to improve the aerosol distribution in
the patients. The study assessed the patients before and after
nebulizer treatment and showed improvement in their FEV1,
PEF, FVC, as well as improvements in the mucociliary clearance.
To further understand the role of aerosol deposition in asthma patients, a study performed by Alcoforado et al. [39] focused on aerosol deposition in 28, stable, moderate-to-severe
asthma patients with mean FEV1< 60% predicted, who were
randomized into four groups: heliox + PEEP at 10 cmH2O,
oxygen + PEEP at 10 cmH2O, heliox alone, and oxygen
alone. The PEEP administration lasted for the time required
to nebulize fenoterol and ipratropium. Inhaled bronchodilators were administered with PEEP along with heliox showed
greater improvements in pulmonary function than by using
heliox alone; however, these improvements were not significantly greater than those in the oxygen + PEEP group [39]. Although differences in pulmonary function tests between the
heliox with PEEP and oxygen with PEEP group were small,
they were attributed to the physical characteristics of the heliox. Heliox, unlike oxygen, has a lower density and higher
viscosity, which allows for less turbulent flow and improved
aerosol deposition within the pulmonary tract.
Although nebulizer therapy in conjunction with positive airway pressure reportedly improved lung function in patients
with asthma, it is important to understand its effects on aerosol deposition in the pulmonary tract during oxygen therapy
and not heliox. Galindo-Filho et al. [40] performed a study in
which they randomized 21 patients and administered inhalation bronchodilators with and without NIV; particles on the
lung were counted with a gamma camera to analyze pulmonary clearance at several times until one hour, despite better
lung functions parameters such as FEV1, FVC, peak expiratory
flow and inspiratory capacity, no inter-group differences were
observed with regard to aerosol deposition.
DISCUSSION
Therefore, bronchial asthma includes numerous phenotypes.
The role of CPAP has been well studied in patients with
asthma considering its effects on the inflammatory cascades,
airway smooth muscle reactivity, and even its effects on bronchodilator therapy. Overall using CPAP may provide an effective therapy for certain patients with asthma [41]. In addition, studies have shown that obese asthmatics are much less
responsive to current inhaled treatment options [42]. Obesity
influences both inflammation and airway mechanics, which
might be important parameters in obesity-related asthma due
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to the effects such as smaller airways, muscle stiffness and hyperresponsiveness in the airway supine position [43]. CPAP
could be used as a rescue therapy in partially controlled or
uncontrolled asthmatics via intermittent daily and/or nightly
use. CPAP may also be used to assist in the inhaled therapy to
ensure better bronchodilatation.
However, there are several unresolved issues that need to be
addressed. It is unclear whether applying CPAP induces reorganization of cytoskeletal and contractile proteins of ASM as
well as extracellular matrix junctions as previously reported
in animal studies. In addition, several factors significantly influence CPAP tolerance and compliance i.e. the adequacy of
humidification, leak control, influence of different types of
masks (nasal or full-face) [41]. These should be considered
in future studies. Nasal intolerance is a frequent, but minor
side effect occurring with CPAP, affecting as many as 50% of
treated patients with OSA [41]. Furthermore, it is important to
understand if peak expiratory flow monitoring or FEV1 are the
appropriate tools to assess the effect of CPAP on the airways.
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